London, United Kingdom

Frederick Arce Vargas

USPTO Granted Patents = 1 


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Frederick Arce Vargas: Innovator in Cancer Treatment

Introduction

Frederick Arce Vargas is a notable inventor based in London, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on enhancing the effectiveness of cancer therapies, particularly through the use of antibodies.

Latest Patents

Frederick Arce Vargas holds a patent for a method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody. This patent describes the use of an anti-CD25 antibody that does not inhibit IL-2-CD25 interaction, which leads to enhanced binding to activating Fc gamma receptors. This mechanism results in effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Furthermore, the combination of this treatment with anti-programmed cell death protein-1 antibodies has been shown to further improve tumor rejection.

Career Highlights

Throughout his career, Frederick has worked with various organizations that focus on cancer research and treatment. Notably, he has been associated with Tusk Therapeutics Ltd. and Cancer Research Technology Limited. His work in these companies has contributed to advancements in cancer therapies and has positioned him as a key figure in the field.

Collaborations

Frederick has collaborated with several professionals in his field, including Anne Goubier and Josephine Salimu. These collaborations have allowed him to enhance his research and develop innovative solutions for cancer treatment.

Conclusion

Frederick Arce Vargas is a pioneering inventor whose work in cancer treatment has the potential to significantly impact patient outcomes. His innovative approaches and collaborations continue to drive advancements in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…